Wikipedia

TGF alpha

Transforming growth factor alpha (TGF-α) is a protein that in humans is encoded by the TGFA gene.[5] As a member of the epidermal growth factor (EGF) family, TGF-α is a mitogenic polypeptide.[6] The protein becomes activated when binding to receptors capable of protein kinase activity for cellular signaling.

TGFA
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesTGFA, TFGA, transforming growth factor alpha, Transforming growth factor - α
External IDsOMIM: 190170; MGI: 98724; HomoloGene: 2431; GeneCards: TGFA; OMA:TGFA - orthologs
Orthologs
SpeciesHumanMouse
Entrez

7039

21802

Ensembl

ENSG00000163235

ENSMUSG00000029999

UniProt

P01135

P48030

RefSeq (mRNA)

NM_001099691
NM_001308158
NM_001308159
NM_003236

NM_031199

RefSeq (protein)

NP_001093161
NP_001295087
NP_001295088
NP_003227

NP_112476
NP_001390047

Location (UCSC)Chr 2: 70.45 – 70.55 MbChr 6: 86.17 – 86.25 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

TGF-α is a transforming growth factor that is a ligand for the epidermal growth factor receptor, which activates a signaling pathway for cell proliferation, differentiation and development. This protein may act as either a transmembrane-bound ligand or a soluble ligand. This gene has been associated with many types of cancers, and it may also be involved in some cases of cleft lip/palate.[5]

Synthesis

edit

TGF-α is synthesized internally as part of a 160 (human) or 159 (rat) amino acid transmembrane precursor.[7] The precursor is composed of an extracellular domain containing a hydrophobic transmembrane domain, 50 amino acids of TGF-α, and a 35-residue-long cytoplasmic domain.[7] In its smallest form, TGF-α has six cysteines linked together via three disulfide bridges. Collectively, all members of the EGF/TGF-α family share this structure. The protein, however, is not directly related to TGF-β.

Limited success has resulted from attempts to synthesize of a reductant molecule to TGF-α that displays a similar biological profile.[8]

Synthesis in the stomach

edit

In the stomach, TGF-α is manufactured within the normal gastric mucosa.[9] TGF-α has been shown to inhibit gastric acid secretion.

Function

edit

TGF-α can be produced in macrophages, brain cells, and keratinocytes. TGF-α induces epithelial development. Considering that TGF-α is a member of the EGF family, the biological actions of TGF-α and EGF are similar. For instance, TGF-α and EGF bind to the same receptor. When TGF-α binds to EGFR it can initiate multiple cell proliferation events.[8] Cell proliferation events that involve TGF-α bound to EGFR include wound healing and embryogenesis. TGF-α is also involved in tumerogenesis and believed to promote angiogenesis.[7]

TGF-α has also been shown to stimulate neural cell proliferation in the adult injured brain.[10]

Receptor

edit

A 170-kDa glycosylated protein known as the EGF receptor binds to TGF-α allowing the polypeptide to function in various signaling pathways.[6] The EGF receptor is characterized by having an extracellular domain that has numerous amino acid motifs. EGFR is essential for a single transmembrane domain, an intracellular domain (containing tyrosine kinase activity), and ligand recognition.[6] As a membrane anchored-growth factor, TGF-α can be cleaved from an integral membrane glycoprotein via a protease.[7] Soluble forms of TGF-α resulting from the cleavage have the capacity to activate EGFR. EGFR can be activated from a membrane-anchored growth factor as well.

When TGF-α binds to EGFR it dimerizes triggering phosphorylation of a protein-tyrosine kinase. The activity of protein-tyrosine kinase causes an autophosphorylation to occur among several tyrosine residues within EGFR, influencing activation and signaling of other proteins that interact in many signal transduction pathways.

 
Epidermal growth factor receptor (EGFR) signaling pathway upon binding to TGF-α.

Animal studies

edit

In an animal model of Parkinson's disease where dopaminergic neurons have been damaged by 6-hydroxydopamine, infusion of TGF-α into the brain caused an increase in the number of neuronal precursor cells.[10] However TGF-α treatment did not result in neurogenesis of dopaminergic neurons.[11]

Human studies

edit

Neuroendocrine system

edit

The EGF/TGF-α family has been shown to regulate luteinizing hormone-releasing hormone (LHRH) through a glial-neuronal interactive process.[6] Produced in hypothalamic astrocytes, TGF-α indirectly stimulates LHRH release through various intermediates. As a result, TGF-α is a physiological component essential to the initiation process of female puberty.[6]

Suprachiasmatic nucleus

edit

TGF-α has also been observed to be highly expressed in the suprachiasmatic nucleus (SCN) (5). This finding suggests a role for EGFR signaling in the regulation of CLOCK and circadian rhythms within the SCN.[12] Similar studies have shown that when injected into the third ventricle TGF-α can suppress circadian locomotor behavior along with drinking or eating activities.[12]

Tumors

edit

This protein shows potential use as a prognostic biomarker in various tumors, like gastric carcinoma.[13] or melanoma has been suggested.[14] Elevated TGF-α is associated with Menetrier's disease, a precancerous condition of the stomach.[15]

Interactions

edit

TGF alpha has been shown to interact with GORASP1[16] and GORASP2.[16]

See also

edit

References

edit
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000163235 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000029999 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b "Entrez Gene: TGFA transforming growth factor alpha".
  6. ^ a b c d e Ojeda SR, Ma YJ, Rage F (September 1997). "The transforming growth factor alpha gene family is involved in the neuroendocrine control of mammalian puberty". Molecular Psychiatry. 2 (5): 355–358. doi:10.1038/sj.mp.4000307. PMID 9322223. S2CID 20268790.
  7. ^ a b c d Ferrer I, Alcántara S, Ballabriga J, Olivé M, Blanco R, Rivera R, et al. (June 1996). "Transforming growth factor-alpha (TGF-alpha) and epidermal growth factor-receptor (EGF-R) immunoreactivity in normal and pathologic brain". Progress in Neurobiology. 49 (2): 99–123. doi:10.1016/0301-0082(96)00009-3. PMID 8844822.
  8. ^ a b McInnes C, Wang J, Al Moustafa AE, Yansouni C, O'Connor-McCourt M, Sykes BD (October 1998). "Structure-based minimization of transforming growth factor-alpha (TGF-alpha) through NMR analysis of the receptor-bound ligand. Design, solution structure, and activity of TGF-alpha 8-50". The Journal of Biological Chemistry. 273 (42): 27357–27363. doi:10.1074/jbc.273.42.27357. PMID 9765263.
  9. ^ Coffey RJ, Gangarosa LM, Damstrup L, Dempsey PJ (October 1995). "Basic actions of transforming growth factor-alpha and related peptides". European Journal of Gastroenterology & Hepatology. 7 (10): 923–7. doi:10.1097/00042737-199510000-00003. PMID 8590135.
  10. ^ a b Fallon J, Reid S, Kinyamu R, Opole I, Opole R, Baratta J, et al. (December 2000). "In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain". Proceedings of the National Academy of Sciences of the United States of America. 97 (26): 14686–14691. Bibcode:2000PNAS...9714686F. doi:10.1073/pnas.97.26.14686. PMC 18979. PMID 11121069.
  11. ^ Cooper O, Isacson O (October 2004). "Intrastriatal transforming growth factor alpha delivery to a model of Parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons". The Journal of Neuroscience. 24 (41): 8924–8931. doi:10.1523/JNEUROSCI.2344-04.2004. PMC 2613225. PMID 15483111.
  12. ^ a b Hao H, Schwaber J (May 2006). "Epidermal growth factor receptor induced Erk phosphorylation in the suprachiasmatic nucleus". Brain Research. 1088 (1): 45–8. doi:10.1016/j.brainres.2006.02.100. PMID 16630586.
  13. ^ Fanelli MF, Chinen LT, Begnami MD, Costa WL, Fregnami JH, Soares FA, et al. (August 2012). "The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer". Histopathology. 61 (2): 153–161. doi:10.1111/j.1365-2559.2011.04139.x. PMID 22582975. S2CID 6566296.
  14. ^ Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, et al. (January 2014). "A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma". Journal of Translational Medicine. 12: 19. doi:10.1186/1479-5876-12-19. PMC 3909384. PMID 24457057.
  15. ^ Coffey RJ, Washington MK, Corless CL, Heinrich MC (January 2007). "Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach". The Journal of Clinical Investigation. 117 (1): 70–80. doi:10.1172/JCI30491. PMC 1716220. PMID 17200708.
  16. ^ a b Barr FA, Preisinger C, Kopajtich R, Körner R (December 2001). "Golgi matrix proteins interact with p24 cargo receptors and aid their efficient retention in the Golgi apparatus". The Journal of Cell Biology. 155 (6): 885–891. doi:10.1083/jcb.200108102. PMC 2150891. PMID 11739402.

Further reading

edit
edit

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://en.wikipedia.org/w/index.php?title=TGF_alpha&oldid=1244466050"